These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21251382)

  • 41. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
    Chung DE; Te AE; Staskin DR; Kaplan SA
    Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.
    Giannitsas K; Perimenis P; Athanasopoulos A; Gyftopoulos K; Nikiforidis G; Barbalias G
    Eur Urol; 2004 Dec; 46(6):776-82; discussion 782-3. PubMed ID: 15548447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New strategies for medical management of overactive bladder in children.
    Schröder A; Thüroff JW
    Curr Opin Urol; 2010 Jul; 20(4):313-7. PubMed ID: 21475074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolterodine.
    Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
    [No Abstract]   [Full Text] [Related]  

  • 57. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.
    Chancellor MB; de Miguel F
    Geriatrics; 2007 May; 62(5):15-24. PubMed ID: 17489643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.